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We aimed to assess the intestinal colonization dynamics by multiple extended-spectrum
cephalosporin-resistant Enterobacteriaceae (ESC-R-Ent) clones in Swiss travelers to
India, a country with high prevalence of these multidrug-resistant pathogens. Fifteen
healthy volunteers (HVs) colonized with ESC-R-Ent after traveling to India who provided
stools before, after, and at 3- and 6-month follow-up are presented in this study. Stools
were enriched in a LB broth containing 3 mg/L cefuroxime and plated in standard
selective media (BLSE, ChromID ESBL, Supercarba) to detect carbapenem- and/or
ESC-R-Ent. At least 5 Enterobacteriaceae colonies were analyzed for each stool
provided. All strains underwent phenotypic tests (MICs in microdilution) and molecular
typing to define bla genes (microarray, PCR/sequencing), clonality (MLST, rep-PCR), and
plasmid content. While only three HVs were colonized before the trip, all participants had
positive stools after returning, but the colonization rate decreased during the follow-up
period (i.e., six HVs were still colonized at both 3 and 6 months). More importantly,
polyclonal acquisition (median of 2 clones, range 1–5) was identified at return in all HVs.
The majority of the Escherichia coli isolates belonged to phylogenetic groups A and B1
and to high diverse non-epidemic sequence types (STs); however, 15% of them belonged
to clonal complex 10 and mainly possessed blaCTX−M−15 genes. F family plasmids were
constantly found (∼80%) in the recovered ESC-R-Ent. Our results indicate a possible
polyclonal acquisition of the ESC-R-Ent via food-chain and/or through an environmental
exposure. For some HVs, prolonged colonization in the follow-up period was observed
due to clonal persistence or presence of the same plasmid replicon types in a new
bacterial host. Travel medicine practitioners, clinicians, and clinical microbiologists who
are facing the returning travelers and their samples for different reasons should be aware
of this important phenomenon, so that better infection control measures, treatment
strategies, and diagnostic tests can be adopted.
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INTRODUCTION
The human gut is increasingly recognized as an important
reservoir of extended-spectrum cephalosporin-resistant
Enterobacteriaceae (ESC-R-Ent), as increasing colonization
rates by these pathogens are observed worldwide (Woerther
et al., 2013). In particular, being colonized by ESBL-producing
Enterobacteriaceae (ESBL-Ent) constitutes a risk factor to
develop future extra-intestinal infections. Despite this fact, silent
carriage of these multidrug-resistant (MDR) bacteria in the
human gut is still poorly studied (Rogers et al., 2011; Van Der Bij
and Pitout, 2012).
The highest colonization prevalence in the healthy population
(∼70%) has been reported in Southeast Asia (Woerther et al.,
2013). Rates increased exponentially over the last decade and
can be linked to several main factors: importation of high-
risk clones (HiRC) via intercontinental travel, inappropriate
use of antibiotics in different settings, high resistance rates in
hospitals, poor hygienic measures (including food-handling),
and high population density (Woerther et al., 2013). Therefore,
it is not surprising that traveling to high prevalence countries
constitute a risk factor to become colonized with these organisms
(Van Der Bij and Pitout, 2012). Moreover, this importation
of bacteria might facilitate the spread of MDR clones in low
prevalence regions (Memish et al., 2003; Rogers et al., 2011). The
problem has been highlighted in previous studies which reported
individuals who acquired infections abroad with organisms
encoding for new life-threatening resistance mechanisms (e.g.,
the first NDM-1 producer in a patient returning to Sweden or the
importation of colistin-resistant MCR-1 producers from India),
or which described resistance mechanisms in new bacterial hosts
and/or genetic structures (Yong et al., 2009; Rogers et al., 2011;
Seiffert et al., 2014; Bernasconi et al., 2016).
In recent years, an increased awareness for polymicrobial
and/or polybacterial infections has also been achieved due to
increased sensitivity of the microbiology diagnostic procedures
(Short et al., 2014; Endimiani and Jacobs, 2016). However, we
note that very few studies have identified multiple ESC-R-Ent
colonizing the gut of healthy individuals (especially returning
travelers) (Paltansing et al., 2013; Girlich et al., 2015; Stoesser
et al., 2015), and very little attention has been attributed to this
phenomenon.
In this work, we aimed to assess the colonization dynamics
by multiple ESC-R-Ent clones acquired during a travel to
India, a high prevalence country of ESC-R-Ent, to further
understand the influence of this phenomenon in the
shaping of the population structure of ESC-R-Ent in the
human gut.
MATERIALS AND METHODS
Recruitment of Volunteers and Study
Design
Fifteen healthy volunteers (HVs) traveling to India were selected
from a larger ongoing study to perform this longitudinal pilot
analysis. These HVs were chosen because they: (i) provided stool
samples before and after traveling (both within 1 week), (ii) were
colonized with ESC-R-Ent after returning from their trip, and
(iii) provided follow-up samples at 3 and 6 months after the trip.
All HVs were recruited at the travel clinic of the Swiss
Tropical and Public Health Institute (Basel) where they signed
an informed consent. Subjects were instructed to self-collect
the native stools in sterile plastic containers and send them
to the Institute for Infectious Diseases of the University
of Bern (Switzerland). Ethical approval was obtained by
the Ethikkommission Nordwest- und Zentralschweiz (EKNZ
239/12).
Sample Processing and Isolate Recovery
Stools (20µg) were enriched overnight in 10 mL of Luria-Bertani
(LB) broth containing a 30 µg cefuroxime disc. Enrichments
were plated (50 µL) in BLSE, ChromID ESBL (bioMérieux),
and a modified Supercarba plate containing imipenem to detect
carbapenem- and/or ESC-R-Ent (Viau et al., 2016).
Species identification was obtained by using the MALDI-TOF
MS (Bruker). At least 5 Enterobacteriaceae colonies per stool
sample were analyzed. Strains were submitted to the double-disk
synergism test (DDST) in cation-adjusted Mueller-Hinton plates
(Becton Dickinson) supplemented with and without cloxacillin
(250 mg/L; Sigma-Aldrich). Isolates yielding DDST results
compatible with ESBL or plasmid-mediated AmpC (pAmpC)
production were further characterized.
Antimicrobial Susceptibility Testing (AST)
and β-lactamase(s) Characterization
ASTs were obtained using the microdilution SentitreTM GNX2F
plate (Trek Diagnostic Systems) and interpreted with EUCAST
breakpoints, except for doxycycline and minocycline for which
CLSI guidelines were used (CLSI, 2016; Eucast, 2016).
β-lactamase genes (bla) were identified using the CT103XL
microarray (Check-Points). PCR/sequencing of the blaESBL and
blapAmpC genes was carried out as previously done (Seiffert et al.,
2013).
Analysis of Clonality and Plasmid Content
The repetitive extragenic palindromic PCR (rep-PCR) was
implemented to assess clonal relatedness (Seiffert et al., 2013).
Multilocus Sequence Typing (MLST) for E. coli (http://mlst.
ucc.ie/mlst/dbs/Ecoli) and K. pneumoniae (http://bigsdb.web.
pasteur.fr/klebsiella/klebsiella.html) were also performed. The
phylogenetic group (PhG) for E. coli was also obtained (Escobar-
Páramo et al., 2004).
Plasmids’ incompatibility groups were assessed with the
multiplex PCR based replicon typing (PBRT) kit (Diatheva).
RESULTS
Demographic and Clinical Characteristics
of Travelers
As shown in Table 1, HVs were mostly females (73.3%) and
middle-aged adults (average of 44 years). None of them was
vegetarian or took anti-acids regularly. The average length of stay
in India was 17.6 days (range 9–30 days). Four subjects reported
having suffered from travelers’ diarrhea. None of the HVs took
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antibiotics during their trip. During the 6-month follow-up
period, several HVs traveled to other destinations (including
India again).
Colonization Timeline and Individual
ESC-R-Ent Clones
Only three out of 15 HVs were colonized by ESC-R-Ent
before traveling, whereas all of them had positive stools after
return (Table 2). During the follow up period, six subjects were
colonized at both 3 and 6 months.
Among the 15 HVs, a total of 143 isolates yielded DDST
phenotypes compatible with either ESBL or pAmpC production.
rep-PCR analysis within each time point narrowed down the
number of ESC-R-Ent isolates to 46 unique clones (data not
shown), consisting of 44 E. coli, one K. pneumoniae, and one
Proteus mirabilis. MLST analysis was performed in this sub-
group of strains. Notably, ESC-R species other than E. coli were
only recovered after traveling (Table 2).
Antibiotic Susceptibility of ESC-R-Ent
As shown in Table 3, none of the isolates detected in the
post-travel stools were resistant to piperacillin/tazobactam or
carbapenems. For non-β-lactams, higher rates of resistance
(∼35–40%) were observed for doxycycline, levofloxacin,
ciprofloxacin, trimethoprim-sulfamethoxazole (STX), whereas
resistance to minocycline and aminoglycosides was ≤20% and
none of the isolates was resistant to tigecycline.
During the follow up periods, the prevalence of resistance to
fluoroquinolones and to minocycline increased, whereas for STX
and aminoglycosides the resistance rates continuously decreased
(Table 3).
β-lactamase Diversity over Time
Pre-travel, the E. coli strains identified were CTX-M-15- and
CTX-M-14 producers (Table 2). Of the 28 isolates recovered after
traveling (26 E. coli, one K. pneumoniae, and one P. mirabilis),
89.3% were ESBL producers and the remaining 10.7% were
pAmpC producers. CTX-M-15 was the most frequent ESBL
identified (92.0%), followed by SHV-12 and VEB-6 (both 4%).
In the follow up period, a decreased in the diversity was
observed. At 3 months, 75% of the strains produced CTX-M-
15, while CTX-M-14 and CMY-42 were produced by 12.5% each.
At 6 months, strains produced CTX-M-15 (42.9%), CTX-M-
1(28.6%), CTX-M-24-like, and CMY-42 (14.3% each).
Population Structure of ESC-R-Ent
E. coli strains were highly diverse, with clones belonging to
different STs and PhGs (Table 2). Before traveling, B23-ST131,
D2-ST648, and A1-ST652 strains were detected.
Among the 26 E. coli identified after returning from the
trip, 22 (88%) yielded an individual ST. Nevertheless, 4 isolates
(15%) belonged to the clonal complex (CC) 10. The PhG A
was predominant (50%), followed by B1 and D (27 and 19%,
respectively), being B2 PhG almost absent.
At 3months, B2 or B1 PhGs were not identified, whereas PhGs
A and D were equally represented. At 6 months, PhG D was the
most frequent (57%), followed by A (29%) and B1 (14%) strains.
With regard to plasmids, those included in the F family were
the most frequently identified (∼80%), even though few other
replicon types were observed (i.e., X1, I1, B/O, and K). F plasmids
were also seen more frequently at 3 and 6 months, whereas other
types identified after traveling were no longer recorded (Table 2).
Shifts in Molecular Characteristics Over
Time
Shifts in themolecular characteristics of the ESC-R-Ent recovered
at the different time points were observed (Table 2). Three
months after traveling, six HVs (HVs #26, 34, 43, 59, 97,
and 100) were decolonized regardless of the number of clones
identified immediately after return. For three HVs not colonized
at 3 months (HVs #23, 37, 41), ESC-R-Ent were identified
at 6 months; compared to each other, these strains carried
a different β-lactamase type in a different ST and had a
different plasmid content. For one subject (HV #29) colonized
before traveling, the clone recovered just after the trip was
different than the initial one; however, 3 months later the initial
clone (D2-ST648-CTX-M-14) reappeared again (Supplemental
Figure 1).
Persistent clones were also observed in HVs #56 and #80 as
the same ST, plasmid content, and β-lactamase were identified
at 3 and 6 months, respectively (Supplemental Figure 1). In
the case of HV #83, there was a shift of clones and β-
lactamases from the stools collected after traveling to those
collected at 3 months; the same clone (D2-ST648) was identified
after 6 months. Persistence of the β-lactamase in the same
mobile genetic element (MGE) was suspected in the case
of HV #50, since the same replicon types identified in the
ST155 strain detected after traveling was identified in the
ST394 detected at 3 and 6 months (Table 2, Supplemental
Figure 1).
Carriage of Multiple ESC-R-Ent
After returning from India, 9 (60%) subjects carried more than
one ESC-R-Ent, with a mean of 1.9 clones and a median of 2
clones (overall range of 1–5). Different E. coli STs were frequently
identified colonizing the same individual harboring the same
ESBL type. Nonetheless, carriage of different β-lactamases was
also observed (HVs #34 and #43).
At 3 and 6 months, carriage of multiple clones was identified
only in HV #68 and HV #37, respectively. In particular, HV #68
had three different CTX-M-15 E. coli producers at 3 months,
whereas HV #37 had at 6 months two different STs harboring
dissimilar CTX-M-types.
When different species were found together with E. coli,
they could carry the same bla (i.e., CTX-M-15-producing K.
pneumoniae for HV #26), or a different gene (i.e., VEB-6-
producing P. mirabilis for HV #37).
DISCUSSION
In this study, we prospectively followed a group of 15 HVs who
returned from India colonized at intestinal level with more than
one ESC-R-Ent clone. We emphasize that only a few studies have
explored the issue of the polyclonal colonization of travelers with
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TABLE 3 | Distribution of β-lactamase types, antibiotic resistance rates and E. coli phylogenetic groups for the 15 volunteers.
Overall period Before Traveling After Traveling 3 months after 6 months after
(n = 46, n◦ isolates, %) (n = 3 n◦ isolates, %) (n = 28, n◦ isolates, %) traveling traveling
(n = 8, n◦ isolates, %) (n = 7, n◦ isolates, %)
β-LACTAMASE TYPES
CTX-M-Group 1 36 (78.3) 2 (66.6) 23 (82.1) 6 (75) 5 (71.4)
CTX-M-15 34 (73.9) 2 (66.6) 23 (82.1)a 6 (75) 3 (42.9)
CTX-M-1 2 (4.3) – – – 2 (28.6)
CTX-M-Group 4 3 (6.5) 1 (33.3) – 1 (12.5) 1 (14.3)
CTX-M-14 2 (4.3) 1 (33.3) – 1 (12.5) –
CTX-M-24-like 1 (2.2) – – – 1 (14.3)
SHV-12 1 (2.2) – 1 (3.6) – –
VEB-6 1 (2.2) – 1 (3.6) – –
DHA-1-like 3 (4.3) – 3 (10.7) – –
CMY-42 2 (4.3) – – 1 (12.5) 1 (14.3)
ANTIBIOTIC RESISTANCEb
Amikacin 1 (2.2) 0 1 (3.6) 0 0
Tobramycin 11 (23.9) 2 (66.7) 5 (17.9) 3 (37.5) 1 (14.3)
Gentamicin 6 (13) 2 (66.7) 3 (10.7) 1 (12.5) 0
Ciprofloxacin 19 (41.3) 3 (100) 10 (35.7) 3 (37.5) 3 (42.9)
Levofloxacin 23 (50.0) 3 (100) 11 (39.3) 5 (62.5) 4 (57.1)
Trimethoprim-Sulfamethoxazole 16 (34.8) 3 (100) 10 (35.7) 1 (12.5) 2 (28.6)
Doxycycline 21 (45.7) 1 (33.3) 11 (39.3) 5 (62.5) 4 (57.1)
Minocycline 10 (21.7) 1 (33.3) 6 (21.4) 2 (25) 1 (14.3)
Tigecycline 0 0 0 0 0
Colistin 1 (2.2) 0 1 (3.6) 0 0
Ticarcillin/clavulanate 10 (21.7) 2 (66.7) 4 (14.3) 2 (25) 2 (28.6)
Piperacillin/tazobactam 0 0 0 0 0
Cefotaxime 44 (95.7) 3 (100) 26 (92.9) 8 (100) 7 (100)
Ceftazidime 42 (91.3) 3 (100) 27 (96.4) 8 (100) 4 (57.1)
Cefepime 17 (37) 2 (66.7) 10 (35.7) 2 (25) 3 (42.9)
Aztreonam 42 (91.3) 3 (100) 24 (85.7) 8 (100) 7 (100)
Imipenem 0 0 0 0 0
Ertapenem 0 0 0 0 0
Meropenem 0 0 0 0 0
Doripenem 0 0 0 0 0
E. coli PHYLOGENETIC GROUPS
A 20 (45.5) 1 (33.3) 13 (50) 4 (50) 2 (28.6)
B1 8 (18.2) 0 7 (26.9) 0 1 (14.3)
D 14 (31.8) 1 (33.3) 5 (19.2) 4 (50) 4 (57.1)
B2 2 (4.5) 1 (33.3) 1 (3.8) 0 0
aOne isolates co-carries a TEM-3-like.
bBased on EUCAST breakpoints except for doxycycline and minocycline for which CLSI was used.
these life-threateningGram-negative pathogens (Paltansing et al.,
2013; Girlich et al., 2015; Stoesser et al., 2015).
Antibiotic Susceptibility and β-lactamase
Diversity
The resistance profiles of the recovered ESC-R-Ent isolates
(i.e., higher rates of resistance to fluoroquinolones, STX, and
aminoglycosides) clearly emphasized the limited option available
for antibiotic therapy in case of infection due to these pathogens.
As expected, the most prevalent β-lactamase types identified
in this study were the CTX-M-15 (Kennedy and Collignon, 2010;
Tängdén et al., 2010; Peirano et al., 2011; Östholm-Balkhed
et al., 2013; Paltansing et al., 2013; Kuenzli et al., 2014; Sole
et al., 2014; Lübbert et al., 2015; Ruppé et al., 2015; Valverde
et al., 2015; Barreto Miranda et al., 2016), whereas other β-
lactamases (i.e., SHV-12-like, CMY-2-like, and DHA-type) were
rarely detected (Östholm-Balkhed et al., 2013; Kuenzli et al.,
2014; Sole et al., 2014). The frequent observation of F plasmids
was also consistent with the great dispersion of these MGEs
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carrying blaCTX−M−types among Enterobacteriaceae recovered
from different settings worldwide (Carattoli, 2013; Mathers et al.,
2015).
Population Structure Shifts among
ESC-R-Ent in Returning Travelers
Prior to travel, the HiRC B23-ST131 and D2-ST648 were
identified. These PhGs/STs have been found worldwide
colonizing and/or causing infections in humans, both companion
and food-producing animals, and wildlife (Woodford et al.,
2011; Ewers et al., 2012, 2014; Pitout, 2012; Nakane et al., 2016).
Interestingly, in the HVs analyzed these initial clones were
replaced after the trip to India (Table 2).
Post-travel, the high heterogeneity of clones identified
indicated numerous possible exposure sources with ESC-R-Ent.
Given that isolates belonged mostly to A and B1 PhGs and to
CC10, CC155, or CC23, we speculate that the acquisition of these
clones could be linked to environmental exposure and/or the
food-chain (Paltansing et al., 2013; Kuenzli et al., 2014; Valverde
et al., 2015). Moreover, the fact that we found ESBL-Ent coding
for the same β-lactamase enzymes, which are frequently reported
in food-items and river waters, strengthens this hypothesis (Bajaj
et al., 2015; Upadhyay et al., 2015; Zurfluh et al., 2015).
However, we should note that despite being unlikely, human-
to-human transmission cannot be excluded, since people living
in tropical or sub-tropical climates have PhG A E. coli strains
as the predominant lineages in the gut (Escobar-Páramo et al.,
2004; Tenaillon et al., 2010). One Indian study identified CTX-
M-15-producing E. coli of PhG A as the most frequent ESBL-E.
coli lineage colonizing the gut of healthy individuals (Escobar-
Páramo et al., 2004; Dureja et al., 2014). Furthermore, the
identification of A1-ST3203 in two HVs traveling together (#26
and #59), but having different pre-travel colonization status
(Table 2), may suggest that the acquisition arises from a common
exposure source or human-to-human transmission. Overall, the
increasing recovery of PhG A and B1 E. coli is worrisome, due
to their expansion in the clinical setting associated with the
production of ESBLs (Woodford et al., 2011; Rodrigues et al.,
2015).
In the stools collected at 3 and 6 months, several
epidemiological shifts were observed. The persistence of
the same clone was observed until 3 months for HV #80 and
until 6 months for HV #56. Nevertheless, the identification of
the same replicon types in a different ST, as observed for HV
#50, suggests that in vivo conjugation may occur (van Schaik,
2015). However, we cannot exclude that the different clones
identified during the follow-up can also be associated to new
independent acquisitions, as several of these HVs have traveled
to high prevalence countries during this period (HVs #23, 37,
and 68; Table 1).
Among the different STs that could be consistently identified
over time, ST648 and members of CC10 were the most frequent
(Table 2). In addition, the majority of plasmids recovered
belonged to the F family. This combination of clones and
plasmids, which can easily adapt to the human host, could explain
their persistence in the gut (Paltansing et al., 2013; Titelman
et al., 2014). Intrinsic characteristics of these genetic backgrounds
or factors conferring increased fitness (e.g., usage of alternative
metabolic pathways), might also contribute to the persistent
intestinal colonization (Alteri and Mobley, 2012).
Colonization Dynamics: Hypothetical
Pathways
According to our observations spanning a 6-month period,
several pathways can be drawn when an initially non-colonized
HV travels to a high prevalence setting: (i) clonal persistence after
returning from the trip (e.g., HV #56); (ii) persistence of theMGE
(e.g., HV #50); (iii) detection of a previously unidentified clone
or independent new acquisition (e.g., HV #83), and (iv) clonal
clearance (e.g., HV #26) from the intestinal tract after several
months (Table 2).
In the case of previously colonized HVs, an additional
pathway can be identified, as the initial clone can be still present
after traveling, but below the detection limit and then re-emerges
after some time (e.g., HV #29) (Paltansing et al., 2013). This
phenomenon has been observed in patients colonized after an
infection (Titelman et al., 2014).
Polyclonality: Clinical and Ecological
Implications
In our study, a median of 2 clones were identified in the
stools of travelers after the trip, indicating that a polyclonal
acquisition occurs when visiting a high ESC-R-Ent prevalence
area. Interestingly, HV #68 returned to India in the follow-up
period and then he was found colonized with three unique MDR
clones, emphasizing the risk of polyclonal acquisition in this
region. This overall phenomenon has been already perceived by
other authors (Östholm-Balkhed et al., 2013; Paltansing et al.,
2013; Lübbert et al., 2015; Ruppé et al., 2015; Valverde et al.,
2015). However, only one study reported a mean of 1.8 clones
among the travelers (being the polyclonal acquisition identified
in 46% of them), but no bacterial population structure analysis
was performed (Ruppé et al., 2015).
In our opinion, there are several important implications
associated with the polyclonal acquisition of ESC-R-Ent. On the
clinical level, physicians should be aware that extra-intestinal
infections in patients who recently traveled in high ESC-R-
Ent prevalence region might be due to MDR clones that are
persisting in the gut. Therefore, the antibiotic treatment has to
be tailored according to the ASTs results provided by the clinical
laboratory and not empirically given (Kennedy and Collignon,
2010). At the diagnostic laboratory level, colony picking from
the selective agar plates can lead to the identification of just
one MDR isolate (e.g., identifying an ESBL-Ent ciprofloxacin
susceptible, but not the ESBL-Ent resistant to the antibiotic),
hindering the implementation of proper antibiotic treatment
regiments (Kennedy and Collignon, 2010; Endimiani and Jacobs,
2016). At the colonization level, different pathways are possible.
The genetic background of the bacterium could have a significant
influence on its ability to persist in the gut. Moreover, in vivo
conjugation can also propagate resistance mechanisms and/or
novel adaptive characteristics into new bacterial hosts with
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stronger ability to persistently colonize the human gut (e.g.,
the HiRCs ST131 and ST648), further potentiating the overall
spread of theseMDR pathogens (Baquero et al., 2011; van Schaik,
2015). Moreover, it has also been demonstrated that bacteria
with certain genetic backgrounds (ST131, ST648, and those of
PhG A) do not suffer fitness upon acquisition of MDR plasmids.
Therefore, particular combinations of very fitting STs with MDR
plasmids might favor more successful colonization overtime
(Johnson et al., 2015; Schaufler et al., 2016).
CONCLUSIONS
A high polyclonal acquisition rate of ESC-R-Ent was observed
when HVs traveled to India. These multiple clones can follow
different pathways, ranging from clonal clearance to clonal
and/or MGE persistence in the gut. The genetic backgrounds of
the acquired clones suggest that this acquisition is linked to not
yet well-defined non-human sources, with the food-chain and the
environment being likely potential sources.
The effective implications of these overall findings are
still not completely clear. However, it appears plausible
that travel medicine practitioners, clinicians, and clinical
microbiologists who are facing the returning travelers and their
specimens for different clinical reasons should be aware of
this important phenomenon, so that better infection control
measures, treatment strategies, and diagnostic tests can be
adopted. Studying the factors underlying ESC-R-Ent persistence
in the gut is also extremely important to better devise
decolonization and colonization prevention strategies in the near
future.
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